Hostname: page-component-cd9895bd7-7cvxr Total loading time: 0 Render date: 2024-12-17T20:05:31.941Z Has data issue: false hasContentIssue false
  • English
  • Français

The prospect of new anxiolytic principles

Published online by Cambridge University Press:  18 September 2015

E.J.L. Griez
Get access Rights & Permissions [Opens in a new window]

Extract

Novel anxiolytics notwithstanding, in the latest fifteen years there have been no major innovations in the treatment of anxiety disorders. Fascinating research is going on, but real breakthroughs will require adequate models of disease, based on the disordered physiology of each type of pathological anxiety. In this brief overview, we will address both the field of potential anxiolytics in 1997, and the development of new experimental models of anxiety disorders.

Keywords

Anxiolyticspanicexperimental modelsCO2CCK
Type
Research Article
Information
Acta Neuropsychiatrica , Volume 9 , Issue 2 , June 1997 , pp. 81 - 83
Copyright
Copyright © Cambridge University Press 1997

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Literature

1.Eison, AS, Eison, MS, Stanley, M, et al.Serotonergic mechanisms in the behavioral effects of buspirone and gepirone. Pharmacol Biochem Behav 1966;24:701–7.CrossRefGoogle Scholar
2.Rickeis, K, Downing, R, Sweizer, Eet al.Antidepressants in the treatment of generalized anxiety disorder. Arch gen Psychiat 1993;50:884–95.CrossRefGoogle Scholar
3.Deakin, JFW. 5-HT, antidepressant drugs and the psychosocial origins of depression. J Psychopharmacol 1996;10:31–8.CrossRefGoogle Scholar
4.Robindon, DS, Rickels, K, Feighner, J, et al.Clinical effects on the 5-HT 1A partial agonists in depression: a composite analysis of buspirone in the treatment of depression. J clin Psychopharmacol 1990; 10 Suppl 3:675–765Google Scholar
5.Schipper, J, Tulp, MTM, Berkelmans, B, et al.Preclinical Pharmacology of flesinoxan: a potential analytic and antidepressant drug. Hum Psychopharmacol 1991;6:53–61CrossRefGoogle Scholar
6.Bradford, LD, Stevens, G. Double-blind placebo controlled fixed does studies of flesinoxan in generalized anxiety disorders. Abstracts of the American College of Neuropsychopharmacology, Puerto Rico 1994;pl67Google Scholar
7.Grof, P, Joffe, R, Kennedy, S, Persad, E, et al.An open study of oral flesinoxan, a 5-HT-1A receptor agonist, in treatment-resistant depression. Int clin Psychopharmacol 1993;8:167–72.CrossRefGoogle ScholarPubMed
8.Vliet van, IM, Westenberg, HGM, Boer den, JA. Effects of the 5-HTIA receptor agonist flesinoxan in panic disorder. Psychopharmacol 1996;127:174–80.CrossRefGoogle Scholar
9.Bressa, GM, Marini, S, Gregori, S. Serotonin S2 receptors blockade and generalized anxiety disorders. A double-blind study of ritan-serin and lorazepam. Int J clin pharmacol Res 1987;7:111–9.Google Scholar
10.Bersani, G, Pozzi, F. Marini, Set al.5-HT2 receptor antagonism in dysthymic disorder: a double-blind placebo-controlled study with ritanserin. Acta psychiat scand 1991;83:244–8.CrossRefGoogle ScholarPubMed
11.Katz, RJ, Landau, PS, Lott, M, et al.Serotonergic (5-HT2) mediation of anxiety-therapeutic effects of serazepine in eneralized anxiety disorder. Biol Psychiat 1993;34:41–4.CrossRefGoogle Scholar
12.Lader, MH. Ondansetron in the treatment of anxiety. Presented at the 5th World congress of biological psychiatry, Satellite Symposium, The Role of ondansetron, a novel 5-HT3 antagonist, in the treatment of psychiatric disorders. Florence, 1991; 17–19.Google Scholar
13.Lecrubier, Y, Puech, AJ, Aczona, Aet al.A randomized double-blind placebo-controlled study of tropisetron in the treatment of outpatients with generalized anxiety disorder. Psychopharmacol 1993;112:129–33.CrossRefGoogle ScholarPubMed
14.Sieghart, W. Pharmacology of benzodiazepine receptors: an update. J Psychiat Neurosci 1994;19: 24–9.Google ScholarPubMed
15.Boulenger, JP. Le traitement de l'anxiété généralisée: approches pharmacolo-giques nouvelles. l'Encéphale 1995;21:459–66.Google Scholar
16.Griez, E, Lousberg, H, Hout van den, MA, et al.C02 vulnerability in panic disorder. Psychiat Res 1987;20:87–95.CrossRefGoogle Scholar
17.Perna, G, Battaglia, M. Garberi, A, et al.35% C02 / 65% 02 inhalation test in panic patients. Psychiat Res 1994; 52: 159–71.CrossRefGoogle Scholar
18.Griez, E, Zandbergen, J, Pols, H, et al.Response to 35% Carbon Dioxide as a marker of panic in severe anxiety. Am J Psychiat 1990;147:796–7Google ScholarPubMed
19.Griez, E, Loof de, C, Pols, J, et al.Specific sensitivity of patients with panic attacks to carbon dioxide inhalation. Psychiat Res 1990;31:193–9.CrossRefGoogle ScholarPubMed
20.Perna, G, Barbini, B, Cochi, S, et al.35% C02 challenge in panic and mood disorders. J affect Disord 1995;33:189–94.CrossRefGoogle Scholar
21.Verburg, C, Griez, E, Meijer, J. A 35% Carbon Dioxide challenge in Simple Phobias. Acta psychiat scand 1994;90:420–3.CrossRefGoogle ScholarPubMed
22.Verburg, C, Griez, E, Meijer, J. Discrimination between panic disorder and generalized anxiety disorder by 35% carbon dioxide challenge. Am Psychiat 1995;152:1081–3.Google ScholarPubMed
23.Perna, G, Cochi, S, Bertani, A, et al.35% C02 sensitivity in healthy first degree relatives of patients with panic disorder. Am J Psychiat 1995;152:623–5.Google Scholar
24.Pols, H, Zandbergen, J, Loof de, C, et al.Attenuation of carbon dioxide-induced panic after clonazepam treatment. Acta psychiat scand 1991;84:585–6.CrossRefGoogle ScholarPubMed
25.Pols, H, Hauzer, R, Meijer, J, et al.Fluvoxamine attenuates panic induced by 35% C02 challenge. J clin Psychiat 1996;57:539–42.CrossRefGoogle Scholar
26.Perna, G. Cochi, S, Bertani, A, et al.Pharmacologic effect of toloxatone on reactivity to the 35% carbon dioxide challenge: a single-blind, random, placeb-controlled study. J clin Psychopharmacol 1994;14:414–8.CrossRefGoogle Scholar
27.Bradwejn, J, Koszycki, D, Shriqui, C. Enhances sensitivity to chole-cystokinin tetrapeptide in panic disorder. Clinical and behavioral findings. Arch gen Psychiat 1991;48:603–10.CrossRefGoogle Scholar
28.Bradwejn, J, Koszycki, D. Imipramine antagonism of the panico-genie effects of cholecystokinin thetrapeptide in panic disorder patients. Am J Psychiat 1994;151:261–3.Google ScholarPubMed
29.Bradwejn, J, Koszycki, D. Comparison of the panicogenic effect of cholecystokinin 30-33 and carbon dioxide in panic disorder. Prog Neuropsychopharmacol Biol Psychiat 1991;15:237–9.CrossRefGoogle ScholarPubMed
30.Bradwejn, J, Koszycki, D, Couetoux-du-Tertre, A, et al.The panicogenic effects of cholesystokinin-tetrapeptide are antagonized by L-365, 260, a central cholecystokinin receptor antagonist, in patients with panic disorder. Arch gen Psychiat 1994;51:486–93.CrossRefGoogle ScholarPubMed
31.Kramer, MS, Cutler, NR, Ballenger, JC, et al.A placebo-controlled trial of L-365, 260, a CCKB antagonist, in panic disorder. Biol Psychiat 1995:37:462–6.CrossRefGoogle ScholarPubMed